Impact of radiation therapy on survival in patients with triple-negative breast cancer

被引:46
|
作者
Steward, Lauren T. [1 ]
Gao, Feng [2 ]
Taylor, Marie A. [3 ]
Margenthaler, Julie A. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA
关键词
triple-negative breast cancer; radiation therapy; survival; LOCOREGIONAL RECURRENCE; CHEMOTHERAPY; RECEPTOR; RISK; RADIOTHERAPY;
D O I
10.3892/ol.2013.1700
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) has a poorer prognosis compared with other sub-groups. In the current study, survival associated with locoregional treatment of females with TNBC was investigated. Specifically, 468 patients with stage I-III TNBC treated between 2002 and 2009 were identified. Data included patient and tumor characteristics, treatment received and survival. Data were compared using (2) and Fisher's exact tests, as well as MANOVA. Kaplan-Meier curves were generated. The study cohort had a mean age of 54 +/- 13 years old with a mean follow-up period of 51 +/- 21 months. Of 468 patients, 249 (53%) underwent lumpectomy, 63 (14%) underwent simple mastectomy (SM) and 156 (33%) underwent modified radical mastectomy (MRM). Overall, 263 (56%) received adjuvant radiation, including 178/249 (71%) following lumpectomy, 13/63 (21%) following SM and 72/156 (46%) following MRM (P<0.0001). Following control for potential confounders in univariate tests, adjuvant radiation was associated with improved overall survival in the total cohort (HR, 0.46; 95% CI, 0.31-0.68; P=0.0001). When comparing survival by surgical type, receipt of adjuvant radiation significantly improved survival in the lumpectomy group (HR, 0.30; 95% CI, 0.16-0.58; P=0.0004), but was not associated with improved survival in the SM group (HR, 0.38; 95% CI, 0.05-3.04; P=0.36) or in the MRM group (HR, 0.79; 95% CI, 0.46-1.34; P=0.38). The survival benefit of adjuvant radiation in these TNBC patients is attributed to those undergoing breast-conserving therapy. There was no benefit in either mastectomy group. These data warrant validation from prospective trials, in order to develop tailored locoregional treatment for patients with TNBC.
引用
收藏
页码:548 / 552
页数:5
相关论文
共 50 条
  • [1] Impact of Adjuvant Radiation Therapy on Breast Cancer-Specific Survival in Patients With Triple-Negative Breast Cancer
    Margenthaler, Julie A.
    Cyr, Amy E.
    Zoberi, Imran
    Gao, Feng
    Taylor, Marie
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : 82 - 82
  • [2] IMPACT OF ITRACONAZOLE ON THE SURVIVAL OF HEAVILY PRETREATED PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
    Tsubamoto, H.
    Inoue, K.
    Sonoda, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1036 - 1036
  • [3] Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
    Loap, Pierre
    Loirat, Delphine
    Berger, Frederique
    Rodrigues, Manuel
    Bazire, Louis
    Pierga, Jean-Yves
    Vincent-Salomon, Anne
    Laki, Fatima
    Boudali, Latifa
    Raizonville, Laurence
    Mosseri, Veronique
    Jochem, Anne
    Eeckhoutte, Alexandre
    Diallo, Mamadou
    Stern, Marc-Henri
    Fourquet, Alain
    Kirova, Youlia
    [J]. JAMA ONCOLOGY, 2022, 8 (12) : 1802 - 1808
  • [4] Radiation therapy in the locoregional treatment of triple-negative breast cancer
    Moran, Meena S.
    [J]. LANCET ONCOLOGY, 2015, 16 (03): : E113 - E122
  • [5] Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer
    Zhang, Le
    Dratver, Milana Bochkur
    Yazal, Taha
    Dong, Kevin
    Nguyen, Andrea
    Yu, Garrett
    Dao, Amy
    Dratver, Michael Bochkur
    Duhachek-Muggy, Sara
    Bhat, Kruttika
    Alli, Claudia
    Pajonk, Frank
    Vlashi, Erina
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (01): : 195 - 207
  • [6] Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer -specific survival
    Kindts, I.
    Buelens, P.
    Laenen, A.
    Van Limbergen, E.
    Janssen, H.
    Wildiers, H.
    Weltens, C.
    [J]. BREAST, 2017, 32 : 18 - 25
  • [7] The prognostic impact of age in patients with triple-negative breast cancer
    Liedtke, Cornelia
    Hess, K. R.
    Karn, T.
    Rody, A.
    Kiesel, L.
    Hortobagyi, G. N.
    Pusztai, L.
    Gonzalez-Angulo, A. M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (02) : 591 - 599
  • [8] The prognostic impact of age in patients with triple-negative breast cancer
    Cornelia Liedtke
    K. R. Hess
    T. Karn
    A. Rody
    L. Kiesel
    G. N. Hortobagyi
    L. Pusztai
    A. M. Gonzalez-Angulo
    [J]. Breast Cancer Research and Treatment, 2013, 138 : 591 - 599
  • [9] Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Liedtke, Cornelia
    Mazouni, Chafika
    Hess, Kenneth R.
    Andre, Fabrice
    Tordai, Attila
    Mejia, Jaime A.
    Symmans, W. Fraser
    Gonzalez-Angulo, Ana M.
    Hennessy, Bryan
    Green, Marjorie
    Cristofanilli, Massimo
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) : 1275 - 1281
  • [10] Impact of Itraconazole on the Survival of Heavily Pre-treated Patients with Triple-Negative Breast Cancer
    Tsubamoto, Hiroshi
    Sonoda, Takashi
    Inoue, Kayo
    [J]. ANTICANCER RESEARCH, 2014, 34 (07) : 3839 - 3844